Navigation Links
Trodusquemine in Medical News

Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)

PLYMOUTH MEETING, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced the formation of its Trodusquemine Scientific Advisory Board (the "SAB"), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance ...

Genaera Corporation Board of Directors Dissolves Corporation and Forms Liquidating Trust

...tinued listing, which requires a minimum bid price for the Company's common stock of $1.00. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Announces Results of Special Meeting of Stockholders

...ove a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution). About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors

...able before making any voting or investment decision with respect to the Plan of Dissolution. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera Corporation Implements Cash Conservation Plan

...order to maintain the ability to pursue business development strategies for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Gen...ely $8.1 million. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...

Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph

...o its Form 10-K which was filed on March 3, 2009 with the Securities and Exchange Commission. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera Corporation Announces 2008 Financial Results

...rease in clinical and third-party contract research expenses related to the trodusquemine (MSI-1436) program for the treatment of type 2 diabetes and obesity and an ...mber 31, 2008. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical t...

Genaera to Present at BIO CEO & Investor Conference

...he treatment of type 2 diabetes and obesity, on Tuesday, February 10, 2009 at 2:15 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference

... This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6 About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...

Genaera to Present at Therapeutic Area Partnerships 2008

...6 for the treatment of type 2 diabetes and obesity on Tuesday, November 4, 2008 at 4:20 p.m. (ET). About Genaera Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that i...
Trodusquemine in Medical Technology

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

-Cohort 1 Data Promising for Type 2 Diabetes- PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Ge...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted - PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the tre...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of ...

Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit

PLYMOUTH MEETING, Pa., July 25 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced interim Phase 1 safety and pharmacokinetic (PK) data and new preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesit...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

PLYMOUTH MEETING, Pa., July 14 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today the presentation of new preclinical data on trodusquemine (MSI-1436), a novel inhibitor of PTP-1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, du...

Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Sci...

Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia

New data supports recent IND and forms foundation for upcoming clinical programs PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), G...

Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)

- Second filing provides opportunity for additional indications and increased potential market - PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that the investigational new drug (IND) application submitted to...

Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)

Study in Overweight and Obese Type 2 Diabetics to Assess Safety and Pharmacokinetics in addition to Specialized Secondary Endpoints PLYMOUTH MEETING, Pa., Jan. 17 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-...
Trodusquemine in Biological Technology

Genaera Receives Non-Compliance Notice from Nasdaq

...Company intends to file a certificate of dissolution and delist its common stock from Nasdaq. About Genaera Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma...

Genaera to Present at BIO-Europe 2008

...ientific Officer, will present a company overview on Tuesday, November 18, 2008 at 11:00 a.m. CET. About Genaera Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is...

Genaera Corporation Announces Second Quarter Financial Results

...ases in research and clinical costs related to the trodusquemine (MSI-1436) program for the treatment of obesity an...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ...

Genaera Corporation Elects Paul K. Wotton to Board of Directors

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation to Present at BIO Business Forum

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation Announces First Quarter Financial Results

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ... trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be de...

Genaera Corporation Announces 2007 Financial Results

...uring, research and personnel costs related to the trodusquemine (MSI-1436) program for the treatment of type 2 dia...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may ...

Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference

...focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. ...

Genaera Corporation Announces Third Quarter Financial Results

...emain on track with plan. Positive interim Phase 1 trodusquemine data announced in the quarter is another example o...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...

Genaera to Present at Biotech 2007 and BIO InvestorForum

...rket opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the...ans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM)...
Other Tags
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... December 25, 2014 The report “Stivarga ... focuses on the current treatment landscape, unmet needs, current ... Stivarga is a drug which is used in the ... orally administered and is also prescribed to patients who ... is FDA approved is a multi-kinase inhibitor and it ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... DALLAS , November 18, 2014 ... Security Systems Market by Systems (Video, RFID, Access Control, ... (SEZ, Factories, Hotels, Banks, Government), Component Service Geography - ... Security Systems Market is projected to be around $25 ... Billion by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
Other Contents